Related references
Note: Only part of the references are listed.THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: G PROTEIN-COUPLED RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-emerge 2 trial
Julio Rosenstock et al.
DIABETES CARE (2013)
Direct effect of GLP-1 infusion on endogenous glucose production in humans
M. Seghieri et al.
DIABETOLOGIA (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
Sonal Singh et al.
JAMA INTERNAL MEDICINE (2013)
Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice
Melissa A. Burmeister et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2012)
Consequences of splice variation on Secretin family G protein-coupled receptor function
Sebastian G. B. Furness et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model
Belinda Gier et al.
DIABETES (2012)
Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling
Sarah H. Lockie et al.
DIABETES (2012)
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
A. J. Scheen
DIABETES & METABOLISM (2012)
Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
G. Grunberger et al.
DIABETIC MEDICINE (2012)
Glucagon-Like Peptide-1 Enhances Glucokinase Activity in Pancreatic β-Cells through the Association of Epac2 with Rim2 and Rab3A
Jae-Hyung Park et al.
ENDOCRINOLOGY (2012)
Unraveling oxyntomodulin, GLP1's enigmatic brother
Alessandro Pocai
JOURNAL OF ENDOCRINOLOGY (2012)
Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats
E. Renner et al.
PEPTIDES (2012)
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
Aiying Wang et al.
BMC Pharmacology & Toxicology (2012)
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
Dominique Xavier Brown et al.
JOURNAL OF NUTRITION AND METABOLISM (2012)
GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons
Kathleen J. Griffioen et al.
CARDIOVASCULAR RESEARCH (2011)
Snapin Mediates Incretin Action and Augments Glucose-Dependent Insulin Secretion
Woo-Jin Song et al.
CELL METABOLISM (2011)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
J. K. Berg et al.
DIABETES OBESITY & METABOLISM (2011)
Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes
R. R. Henry et al.
DIABETES OBESITY & METABOLISM (2011)
Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
Scott E. Kanoski et al.
ENDOCRINOLOGY (2011)
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
R. Pratley et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Phospholipase C-ε links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans
Igor Dzhura et al.
ISLETS (2011)
Vagal control of pancreatic β-cell proliferation
James Lausier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor
Martha C. Washington et al.
BRAIN RESEARCH (2010)
Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study
Sabine Arnolds et al.
DIABETES CARE (2010)
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
Wolfgang Glaesner et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2010)
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
J. S. Nachnani et al.
DIABETOLOGIA (2010)
Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase
Monika Malm-Erjefalt et al.
DRUG METABOLISM AND DISPOSITION (2010)
Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor
Kiwon Ban et al.
ENDOCRINOLOGY (2010)
GLP-1 Mediates Antiapoptotic Effect by Phosphorylating Bad through a β-Arrestin 1-mediated ERK1/2 Activation in Pancreatic β-Cells
Julie Quoyer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Glucagon-like Peptide-1 Increases β-Cell Glucose Competence and Proliferation by Translational Induction of Insulin-like Growth Factor-1 Receptor Expression
Marion Cornu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Hepatic-Portal Vein Infusions of Glucagon-Like Peptide-1 Reduce Meal Size and Increase c-Fos Expression in the Nucleus Tractus Solitarii, Area Postrema and Central Nucleus of the Amygdala in Rats
I. Baumgartner et al.
JOURNAL OF NEUROENDOCRINOLOGY (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening
Cassandra Koole et al.
MOLECULAR PHARMACOLOGY (2010)
Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis
Eva Tomas et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Differences in the Central Anorectic Effects of Glucagon-Like Peptide-1 and Exendin-4 in Rats
Jason G. Barrera et al.
DIABETES (2009)
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes A randomized controlled trial exploring weekly, biweekly, and monthly dosing
Julio Rosenstock et al.
DIABETES CARE (2009)
Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Diana L. Williams et al.
ENDOCRINOLOGY (2009)
Direct Control of Peripheral Lipid Deposition by CNS GLP-1 Receptor Signaling Is Mediated by the Sympathetic Nervous System and Blunted in Diet-Induced Obesity
Ruben Nogueiras et al.
JOURNAL OF NEUROSCIENCE (2009)
Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions
Gregory M. Holmes et al.
JOURNAL OF PHYSIOLOGY-LONDON (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
Adil E. Bharucha et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2008)
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
Kiwon Ban et al.
CIRCULATION (2008)
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity
Cendrine Cabou et al.
DIABETES (2008)
Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake
Darleen A. Sandoval et al.
DIABETES (2008)
Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects
Haiqinq Dai et al.
DIABETES OBESITY & METABOLISM (2008)
Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation
Matthew R. Hayes et al.
ENDOCRINOLOGY (2008)
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption
Chizumi Yamada et al.
ENDOCRINOLOGY (2008)
Expression of the GLP-1 Receptor in Mouse, Rat, and Human Pancreas
Ditte Tornehave et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2008)
Pattern of Intra-Family Hetero-Oligomerization Involving the G-Protein-Coupled Secretin Receptor
Kaleeckal G. Harikumar et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2008)
Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells
Guoxin Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome
P. M. Hellstrom et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2008)
GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide
Dariush Elahi et al.
OBESITY (2008)
β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells
Noriyuki Sonoda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by CAMP
Tadao Shibasaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
β cell-specific deficiency of the stimulatory G protein α-subunit Gsα leads to reduced β cell mass and insulin-deficient diabetes
Tao Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons
Shuxia Wan et al.
PEPTIDES (2007)
Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding
Judith Korner et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2007)
Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats
Torsten P. Vahl et al.
ENDOCRINOLOGY (2007)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Two cAMP-dependent pathways differentially regulate exocytosis of large dense-core and small vesicles in mouse β-cells
Hiroyasu Hatakeyama et al.
JOURNAL OF PHYSIOLOGY-LONDON (2007)
Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs
Rasmus Jorgensen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
P. Schlatter et al.
REGULATORY PEPTIDES (2007)
Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV
Jun Feng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
GLP-1 receptor expression in human tumors and human normal tissues:: Potential for in vivo targeting
Meike Koerner et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons
S. Wan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2007)
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Gang Xu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs
Carl Frederik Nagell et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
JJ Meier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Rapid glucose sensing by protein kinase A for insulin exocytosis in mouse pancreatic islets
H Hatakeyama et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
LA Nikolaidis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
A Plamboeck et al.
DIABETOLOGIA (2005)
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile)
I Brandt et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
JJ Meier et al.
DIABETES (2005)
β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release
I Franklin et al.
DIABETES (2005)
The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway
CR Abbott et al.
BRAIN RESEARCH (2005)
Exenatide (Exendin-4) improves insulin sensitivity and β-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
BR Gedulin et al.
ENDOCRINOLOGY (2005)
Effect of GLP-1 on glucose transport and its cell signalling in human myocytes
N González et al.
REGULATORY PEPTIDES (2005)
The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem
E Alvarez et al.
JOURNAL OF NEUROCHEMISTRY (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes
KB Degn et al.
DIABETES (2004)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
JJ Meier et al.
DIABETES (2004)
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
F Preitner et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
A Nakagawa et al.
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL (2004)
The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211
T Bock et al.
APMIS (2003)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
L Farilla et al.
ENDOCRINOLOGY (2003)
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
RL Prigeon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
GLP-1 derivative liraglutide in rats with β-cell deficiencies:: influence of metabolic state on β-cell mass dynamics
J Sturis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
MJ During et al.
NATURE MEDICINE (2003)
Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes
GS Meneilly et al.
DIABETES CARE (2003)
SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells
L Eliasson et al.
JOURNAL OF GENERAL PHYSIOLOGY (2003)
Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor
J Buteau et al.
DIABETES (2003)
Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1
A. Bulotta et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2002)
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
L Farilla et al.
ENDOCRINOLOGY (2002)
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice
B Rolin et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2002)
Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice
Q Wang et al.
DIABETOLOGIA (2002)
Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism
PE Light et al.
MOLECULAR ENDOCRINOLOGY (2002)
Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes
MA Luque et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans
J Schirra et al.
GUT (2002)
NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1
MC Lawrence et al.
DIABETES (2002)
Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion
AM Lambeir et al.
FEBS LETTERS (2001)
cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic β-cells
GX Kang et al.
JOURNAL OF PHYSIOLOGY-LONDON (2001)
Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age
C Tourrel et al.
DIABETES (2001)
Transbuccal peptide delivery: stability and in vitro permeation studies on endomorphin-1
AP Bird et al.
JOURNAL OF CONTROLLED RELEASE (2001)
Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells
HX Hui et al.
DIABETES (2001)
Glucose sensing in pancreatic beta-cells - A model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus
FC Schuit et al.
DIABETES (2001)
cAMP-GEFII is a direct target of cAMP in regulated exocytosis
N Ozaki et al.
NATURE CELL BIOLOGY (2000)
Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A - Independent activation of the rat insulin I gene cAMP response element
G Skoglund et al.
DIABETES (2000)
Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes
A Vella et al.
DIABETES (2000)
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
DA Stoffers et al.
DIABETES (2000)
Share Paper
